AXIM BIOTECHNOLOGIES, INC.

AXIM ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016
Assets
Cash & Equivalents $156.5K $47.3K $453.0K $457.2K $511.6K $1.8M $2.1M $713.3K
Accounts Receivable $315.8K $0
Inventory $487.8K $9.8K $8.8K $38.4K
Total Current Assets $156.5K $104.0K $636.6K $713.1K $1.6M $2.0M $2.1M $1.4M
Property, Plant & Equipment $134.1K $93.8K $116.8K $104.1K $2.2K $5.6K $8.9K $12.3K
Goodwill $0 $2.5M $0
Intangible Assets (Excl. Goodwill) $50.5K $53.7K $63.2K $63.2K
Total Assets $4.1M $4.2M $5.3M $11.3M $1.7M $2.1M $2.2M $1.4M
Liabilities
Accounts Payable
Total Current Liabilities $6.0M $3.4M $2.6M $1.5M $3.4M $3.3M $7.7M $3.0M
Long-Term Debt
Total Liabilities $11.8M $9.0M $7.7M $9.7M $8.5M $8.2M $8.5M $3.8M
Stockholders' Equity
Retained Earnings $-72.2M $-64.1M $-57.9M $-41.8M $-35.4M $-29.0M $-22.2M $-18.1M
Total Stockholders' Equity $-7.7M $-4.8M $-2.3M $1.6M $-6.8M $-6.1M $-6.3M $-2.4M
← Newer Page 1 of 2 Older →